Скачать или смотреть Use of Vectra DA to Track Rheumatoid Arthritis (RA) Disease Activity

Marie, an RA Patient Advocate, shares her personal experience with Vectra® DA, an advanced blood test that measures disease activity in rheumatoid arthritis (RA). Marie talks about the process of getting tested and the simple 1 to 100 (lower is better) scoring system with Vectra DA that classifies RA into low, moderate or high disease activity. Vectra DA must be ordered by a healthcare provider and is intended to aid in the assessment of disease activity in RA patients when used in conjunction with standard clinical assessment.

Marie is a person living with rheumatoid arthritis, Sjogren's syndrome, and systemic lupus. She is a passionate patient advocate and serves as a consultant to Crescendo Bioscience. This video reflects her own personal opinions and views. Her comments in this video are not scripted and are in her own words.

Vectra DA must be ordered by a healthcare provider and is intended to aid in the assessment of disease activity in RA patients when used in conjunction with standard clinical assessment.

Crescendo Bioscience is regulated under and qualified to perform high complexity testing under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Vectra DA was developed and its performance characteristics determined by Crescendo Bioscience. Vectra DA has not been evaluated by the U.S. Food and Drug Administration.

#VectraDA
https://vectrada.com/
https://www.crescendobio.com/
  / vectrada  
  / vectrada  
   / crescendobioscience  

About Vectra® DA
Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity. It integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit: www.Vectra-DA.com.

About Crescendo Bioscience
Crescendo Bioscience Inc., a wholly-owned subsidiary of Myriad Genetics, Inc., located in South San Francisco, CA, is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for RA and other autoimmune diseases. Our mission is to provide rheumatologists with deeper clinical insights and help enable more effective management of patients with autoimmune and inflammatory diseases. Our goal is to create a broad portfolio of specialty diagnostic tests that will enable more effective patient management and improve patient outcomes. For more information, please visit the company website at www.CrescendoBio.com.

Vectra DA is validated for use in adults diagnosed with RA. Test results are intended to aid in the assessment of disease activity in RA patients when used in conjunction with standard clinical assessment. This test is not intended or validated to diagnose RA.

©2017 Crescendo Bioscience, Inc. All rights reserved. Vectra, Crescendo Bioscience, and the associated logos are trademarks or registered trademarks of Crescendo Bioscience, Inc. in the United States and other jurisdictions.